Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID ANTONIO MEDINA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1588805824
CMS profile
207389
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$10,263.33

176 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID ANTONIO MEDINA

NPI 1588805824 · CMS profile ID 207389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588805824?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID ANTONIO MEDINA, NPI 1588805824, CMS profile ID 207389. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588805824?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID ANTONIO MEDINA, NPI 1588805824, CMS profile ID 207389. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588805824?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID ANTONIO MEDINA, NPI 1588805824, CMS profile ID 207389, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588805824?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

176 matching records · $10,263.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 176 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 176.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IRONSHORE PHARMACEUTICALS INC. $15.2409/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146256225 CMS
ACADIA Pharmaceuticals Inc $139.5309/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147984160 CMS
Otsuka America Pharmaceutical, Inc. $124.9909/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118940698 CMS
Neurocrine Biosciences, Inc. $28.4809/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150829540 CMS
Otsuka America Pharmaceutical, Inc. $22.0509/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118940696 CMS
Teva Pharmaceuticals USA, Inc. $4.1309/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497587 CMS
Lundbeck LLC $18.3308/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145945354 CMS
Noven Therapeutics, LLC $13.2208/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084819878 CMS
Neurocrine Biosciences, Inc. $27.4008/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150832774 CMS
ABBVIE INC. $18.5708/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105013334 CMS
Neurocrine Biosciences, Inc. $92.6408/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150812564 CMS
Alkermes, Inc. $28.4608/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120552820 CMS
Neurocrine Biosciences, Inc. $27.7108/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150832026 CMS
Vanda Pharmaceuticals Inc. $34.2708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133912534 CMS
Teva Pharmaceuticals USA, Inc. $24.2708/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497571 CMS
Supernus Pharmaceuticals, Inc. $8.5008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147827199 CMS
Lundbeck LLC $22.7008/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145945352 CMS
Neurocrine Biosciences, Inc. $10.1708/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150882421 CMS
Neurocrine Biosciences, Inc. $6.0008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150887045 CMS
Neurocrine Biosciences, Inc. $2.8908/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150890084 CMS
Neurocrine Biosciences, Inc. $2.6508/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150890410 CMS
Teva Pharmaceuticals USA, Inc. $18.2108/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497563 CMS
Alkermes, Inc. $28.0807/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120552818 CMS
ACADIA Pharmaceuticals Inc $89.6407/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147984158 CMS
Teva Pharmaceuticals USA, Inc. $10.4807/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497561 CMS
ABBVIE INC. $9.7707/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105013332 CMS
Janssen Pharmaceuticals, Inc $21.8007/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077972294 CMS
Alkermes, Inc. $28.6507/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120552816 CMS
Neurocrine Biosciences, Inc. $21.7907/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150852168 CMS
Vanda Pharmaceuticals Inc. $27.7707/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133912532 CMS
LivaNova USA, Inc. $76.4607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152799675 CMS
Janssen Pharmaceuticals, Inc $28.1007/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077972092 CMS
ACADIA Pharmaceuticals Inc $20.8307/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147984156 CMS
Neurocrine Biosciences, Inc. $29.9507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150826022 CMS
Teva Pharmaceuticals USA, Inc. $6.0407/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497559 CMS
Neurocrine Biosciences, Inc. $22.5706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150848252 CMS
Neurocrine Biosciences, Inc. $1.6906/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150891597 CMS
Alkermes, Inc. $29.6006/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120552814 CMS
LivaNova USA, Inc. $65.7806/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152799677 CMS
Teva Pharmaceuticals USA, Inc. $24.0106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497539 CMS
Neurocrine Biosciences, Inc. $27.3306/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150832890 CMS
Otsuka America Pharmaceutical, Inc. $18.8706/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118940694 CMS
Axsome Therapeutics, Inc. $25.7606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148275696 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $125.0006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118071461 CMS
Neurocrine Biosciences, Inc. $15.0306/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150875082 CMS
ACADIA Pharmaceuticals Inc $13.4006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147984154 CMS
Teva Pharmaceuticals USA, Inc. $14.0106/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151497537 CMS
Alkermes, Inc. $15.0805/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120552812 CMS
Lundbeck LLC $19.6105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145945350 CMS
Neurocrine Biosciences, Inc. $15.4105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150873788 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,477.77 43
PY2020 $6,018.25 55
PY2021 $2,605.92 96
PY2022 $63,226.07 188
PY2023 $32,872.26 196
PY2024 $10,263.33 176
PY2025 $69,790.60 308

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $224,362.36 90
PY2024 Principal investigator $116,617.76 56
PY2023 Principal investigator $392,547.31 374
PY2022 Principal investigator $62,422.59 21
PY2021 Principal investigator $3,974.90 2
PY2020 Principal investigator $12,961.00 3
PY2019 Recipient $1,544.28 7
PY2019 Principal investigator $90,339.95 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,505.68 12/31/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder No dispute reported 06/30/2026 1202533035
Principal investigator 1 Janssen Research & Development, LLC $2,276.00 12/22/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175374537
Principal investigator 1 Janssen Research & Development, LLC $5,866.00 12/04/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175374543
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 11/19/2025 Non-covered Recipient Entity
Nova Psychiatry Inc.
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044470
Principal investigator 1 LivaNova USA, Inc. $1,163.75 11/11/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549470
Principal investigator 1 LivaNova USA, Inc. $458.85 11/11/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549474
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31.19 10/27/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235995139
Principal investigator 1 LivaNova USA, Inc. $1,050.70 10/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549364
Principal investigator 1 LivaNova USA, Inc. $1,163.75 10/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549368
Principal investigator 1 LivaNova USA, Inc. $66.50 10/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549372
Principal investigator 1 LivaNova USA, Inc. $1,163.75 10/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549457
Principal investigator 1 LivaNova USA, Inc. $66.50 10/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549461
Principal investigator 1 Janssen Research & Development, LLC $6,281.00 09/26/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31,769.97 09/17/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804170
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 09/15/2025 Non-covered Recipient Entity
Nova Psychiatry Inc.
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044468
Principal investigator 1 LivaNova USA, Inc. $1,163.75 09/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549355
Principal investigator 1 LivaNova USA, Inc. $66.50 09/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549360
Principal investigator 1 LivaNova USA, Inc. $1,163.75 09/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549453
Principal investigator 1 Janssen Research & Development, LLC $7,186.00 09/01/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374526
Principal investigator 1 LivaNova USA, Inc. $458.85 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549352
Principal investigator 1 LivaNova USA, Inc. $1,050.70 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549404
Principal investigator 1 LivaNova USA, Inc. $1,050.70 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549408
Principal investigator 1 LivaNova USA, Inc. $1,163.75 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549412
Principal investigator 1 LivaNova USA, Inc. $1,163.75 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549415
Principal investigator 1 LivaNova USA, Inc. $1,163.75 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549420
Principal investigator 1 LivaNova USA, Inc. $1,163.75 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549424
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549429
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549433
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549438
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549442
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549446
Principal investigator 1 LivaNova USA, Inc. $458.85 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549450
Principal investigator 1 LivaNova USA, Inc. $1,050.70 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549601
Principal investigator 1 LivaNova USA, Inc. $1,163.75 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549605
Principal investigator 1 LivaNova USA, Inc. $66.50 08/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549608
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.45 07/28/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804150
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.45 07/28/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804152
Principal investigator 1 Janssen Research & Development, LLC $15,290.00 07/28/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374495
Principal investigator 1 LivaNova USA, Inc. $1,345.00 07/22/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556895
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,146.26 07/21/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804144
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,900.00 07/21/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804146
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.45 07/21/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804148
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $555.75 07/18/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804166
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $468.00 07/18/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804168
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,452.41 07/16/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,027.81 07/16/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804142
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $219.46 07/13/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804138
Principal investigator 1 LivaNova USA, Inc. $90.00 06/17/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556777
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 06/13/2025 Non-covered Recipient Entity
Nova Psychiatry Inc.
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044466
Principal investigator 1 LivaNova USA, Inc. $1,163.75 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549526
Principal investigator 1 LivaNova USA, Inc. $1,050.70 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549530
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549533
Principal investigator 1 LivaNova USA, Inc. $700.00 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549538
Principal investigator 1 LivaNova USA, Inc. $1,163.75 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549566
Principal investigator 1 LivaNova USA, Inc. $1,163.75 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549569
Principal investigator 1 LivaNova USA, Inc. $1,163.75 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549573
Principal investigator 1 LivaNova USA, Inc. $1,163.75 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549577
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549580
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549584
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549587
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549592
Principal investigator 1 LivaNova USA, Inc. $66.50 06/10/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549597
Principal investigator 1 Janssen Research & Development, LLC $19,151.00 05/29/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374487
Principal investigator 1 LivaNova USA, Inc. $1,163.75 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549507
Principal investigator 1 LivaNova USA, Inc. $1,050.70 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549511
Principal investigator 1 LivaNova USA, Inc. $66.50 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549516
Principal investigator 1 LivaNova USA, Inc. $458.85 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549519
Principal investigator 1 LivaNova USA, Inc. $585.20 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549523
Principal investigator 1 LivaNova USA, Inc. $1,050.70 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549554
Principal investigator 1 LivaNova USA, Inc. $66.50 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549558
Principal investigator 1 LivaNova USA, Inc. $66.50 05/09/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549561
Principal investigator 1 ABBVIE INC. $15,000.00 05/07/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202483343
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,425.00 04/29/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804164
Principal investigator 1 Janssen Research & Development, LLC $6,669.00 04/28/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374503
Principal investigator 1 LivaNova USA, Inc. $1,050.70 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549485
Principal investigator 1 LivaNova USA, Inc. $0.20 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549490
Principal investigator 1 LivaNova USA, Inc. $66.50 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549495
Principal investigator 1 LivaNova USA, Inc. $53.20 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549499
Principal investigator 1 LivaNova USA, Inc. $385.70 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549503
Principal investigator 1 LivaNova USA, Inc. $1,050.70 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549541
Principal investigator 1 LivaNova USA, Inc. $1,050.70 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549545
Principal investigator 1 LivaNova USA, Inc. $66.50 04/08/2025 Non-covered Recipient Entity
Nova Psychiatry, Inc
RECOVER No dispute reported 06/30/2026 1245549549
Principal investigator 1 Janssen Research & Development, LLC $22,921.00 03/28/2025 Non-covered Recipient Entity
NOVA PSYCHIATRY INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175374508
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,619.50 03/26/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804162
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,342.18 03/17/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) No dispute reported 06/30/2026 1220804136
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,546.42 03/05/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804160
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 02/12/2025 Non-covered Recipient Entity
Nova Psychiatry Inc.
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044464
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,092.50 01/24/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804158
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,104.72 01/22/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804156
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,340.46 01/06/2025 Non-covered Recipient Entity
Nova Psychiatry Inc
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220804154